Axogen Inc vs Oatly Group AB - ADR — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Oatly Group AB - ADR trades at $9.98 (market cap $304.76M). The key difference: Axogen Inc is far larger — about 6.8× Oatly Group AB - ADR's market cap, and Axogen Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| AXGN | OTLY | |
|---|---|---|
Market Cap | $2.06B | $304.76M |
Sector | Technology | Consumer Staples |
52-Week High | $46.19 | $18.54 |
52-Week Low | $11.28 | $8.03 |
Enterprise Value | $1.98B | $802.37M |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Oatly (OTLY) trades at $10.00, up 1.52% today, showing modest momentum despite ongoing financial challenges. The company maintains a low P/S ratio of 0.35 but suffers from negative profitability metrics including a -17.06% net income margin and -245.57% ROE. Recent Q1 2026 earnings beat expectations with a smaller loss than projected, while technical indicators show mixed signals with an overall bullish bias. Cash flow remains negative but has improved from previous years, with operating cash burn narrowing to -$24 million in 2025.
Oatly faces significant execution risks with persistent losses and high debt levels (66.53% debt-to-asset ratio), though revenue growth continues and cash burn shows improvement. Analyst sentiment is divided with 44% buy ratings but 50% hold recommendations, reflecting cautious optimism about the company's turnaround potential amid competitive pressures in the plant-based beverage market.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →